Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Compare

1,024 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AVTX Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Avalo

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AVTX Stock 12 Month Forecast

Average Price Target

$33.99

▲(153.66% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is $33.99 with a high forecast of $48.00 and a low forecast of $19.96. The average price target represents a 153.66% change from the last price of $13.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","26":"$26","49":"$49","14.5":"$14.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.99,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.959989,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.5,26,37.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.02,12.018461538461539,15.016923076923078,18.015384615384615,21.013846153846153,24.012307692307694,27.01076923076923,30.009230769230772,33.00769230769231,36.00615384615385,39.00461538461539,42.00307692307693,45.00153846153846,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.02,10.94076923076923,12.861538461538462,14.782307692307693,16.703076923076924,18.623846153846152,20.544615384615383,22.465384615384615,24.386153846153846,26.306923076923077,28.22769230769231,30.14846153846154,32.06923076923077,{"y":33.99,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.02,9.861537615384615,10.70307523076923,11.544612846153846,12.386150461538461,13.227688076923076,14.069225692307693,14.910763307692308,15.752300923076923,16.59383853846154,17.435376153846153,18.27691376923077,19.118451384615383,{"y":19.959989,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.05,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.43,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$48.00

Average Price Target$33.99

Lowest Price Target$19.96

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Julian Harrison

BTIG

$40

Buy

198.51%

Upside

Reiterated

09/29/25

Avalo Therapeutics (AVTX) Receives a Buy from BTIGAvalo Therapeutics (AVTX, Buy, $40 PT) ... VELA Data Likely a Competition Clearing Event in HS, Boding Well for AVTX-009; Reiterate BUY

Leland Gershell

Oppenheimer

$35

Buy

161.19%

Upside

Reiterated

09/29/25

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

Mitchell Kapoor

H.C. Wainwright

$15→$25

Buy

86.57%

Upside

Reiterated

09/18/25

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX), Phathom Pharmaceuticals (NASDAQ: PHAT) and Plus Therapeutics (NASDAQ: PSTV)

Stacy Ku

TD Cowen

―

Buy

―

Reiterated

09/17/25

Yasmeen Rahimi

Piper Sandler

$48

Buy

258.21%

Upside

Reiterated

09/11/25

Avalo Therapeutics (AVTX) Receives a Buy from Piper Sandler

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Initiated

08/15/25

Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$54.01→$19.96

Buy

48.96%

Upside

Initiated

08/06/25

Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank

Alex Thompson CFA

Stifel Nicolaus

$36

Buy

168.66%

Upside

Reiterated

07/28/25

Stifel Nicolaus Keeps Their Buy Rating on Avalo Therapeutics (AVTX)

Kambiz Yazdi

Jefferies

$23

Buy

71.64%

Upside

Initiated

03/25/25

Promising Outlook for Avalo Therapeutics' AVTX-009 in HS Treatment

Robert Driscoll

Wedbush

$18

Buy

34.33%

Upside

Initiated

02/20/25

Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush

Dev Prasad

Lucid Capital

$24

Buy

79.10%

Upside

Initiated

12/17/24

Avalo Therapeutics initiated with a Buy at Lucid CapitalAvalo Therapeutics initiated with a Buy at Lucid Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Julian Harrison

BTIG

$40

Buy

198.51%

Upside

Reiterated

09/29/25

Avalo Therapeutics (AVTX) Receives a Buy from BTIGAvalo Therapeutics (AVTX, Buy, $40 PT) ... VELA Data Likely a Competition Clearing Event in HS, Boding Well for AVTX-009; Reiterate BUY

Leland Gershell

Oppenheimer

$35

Buy

161.19%

Upside

Reiterated

09/29/25

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

Mitchell Kapoor

H.C. Wainwright

$15→$25

Buy

86.57%

Upside

Reiterated

09/18/25

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (NASDAQ: AVTX), Phathom Pharmaceuticals (NASDAQ: PHAT) and Plus Therapeutics (NASDAQ: PSTV)

Stacy Ku

TD Cowen

―

Buy

―

Reiterated

09/17/25

Yasmeen Rahimi

Piper Sandler

$48

Buy

258.21%

Upside

Reiterated

09/11/25

Avalo Therapeutics (AVTX) Receives a Buy from Piper Sandler

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Initiated

08/15/25

Avalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAvalo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$54.01→$19.96

Buy

48.96%

Upside

Initiated

08/06/25

Avalo Therapeutics (AVTX) Receives a Buy from Berenberg Bank

Alex Thompson CFA

Stifel Nicolaus

$36

Buy

168.66%

Upside

Reiterated

07/28/25

Stifel Nicolaus Keeps Their Buy Rating on Avalo Therapeutics (AVTX)

Kambiz Yazdi

Jefferies

$23

Buy

71.64%

Upside

Initiated

03/25/25

Promising Outlook for Avalo Therapeutics' AVTX-009 in HS Treatment

Robert Driscoll

Wedbush

$18

Buy

34.33%

Upside

Initiated

02/20/25

Avalo Therapeutics initiated with an Outperform at WedbushAvalo Therapeutics initiated with an Outperform at Wedbush

Dev Prasad

Lucid Capital

$24

Buy

79.10%

Upside

Initiated

12/17/24

Avalo Therapeutics initiated with a Buy at Lucid CapitalAvalo Therapeutics initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avalo Therapeutics

1 Month

xxx

Success Rate

3/4 ratings generated profit

Average Return

+5.00%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +5.00% per trade.

3 Months

xxx

Success Rate

2/4 ratings generated profit

Average Return

+33.38%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +33.38% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

4/4 ratings generated profit

Average Return

+65.77%

reiterated a buy rating 6 days ago

Copying Julian Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +65.77% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+65.77%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +65.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVTX Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AVTX has received 16 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. AVTX average Analyst price target in the past 3 months is 33.99.

Each month's total comprises the sum of three months' worth of ratings.

AVTX Financial Forecast

AVTX Earnings Forecast

Next quarter’s earnings estimate for AVTX is -$1.66 with a range of -$1.85 to -$1.25. The previous quarter’s EPS was -$1.92. AVTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year AVTX has Preformed in-line its overall industry.

AVTX Sales Forecast

Next quarter’s sales forecast for AVTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year AVTX has Preformed in-line its overall industry.

AVTX Stock Forecast FAQ

What is AVTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Avalo Therapeutics’s 12-month average price target is 33.99.

What is AVTX’s upside potential, based on the analysts’ average price target?

Avalo Therapeutics has 153.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AVTX a Buy, Sell or Hold?

Avalo Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Avalo Therapeutics’s price target?

The average price target for Avalo Therapeutics is 33.99. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $19.96. The average price target represents 153.66% Increase from the current price of $13.4.

What do analysts say about Avalo Therapeutics?

Avalo Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of AVTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

AVTX Analyst Ratings

AVTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avalo Therapeutics

AVTX Analyst Recommendation Trends

AVTX Financial Forecast

AVTX Earnings Forecast

AVTX Sales Forecast

AVTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts